Litigation Details for Medicines Company v. Hospira Inc. (D. Del. 2010)

« Back to Dashboard

Medicines Company v. Hospira Inc. (D. Del. 2010)

Docket		Date Filed	2010-08-19
Court	District Court, D. Delaware	Date Terminated	2014-04-15
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	7,582,727; 7,598,343
Link to Docket	External link to docket

Details for Medicines Company v. Hospira Inc. (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-08-19				External link to document

The Medicines Company v. Hospira Inc. Litigation Summary, 1:10-cv-00700

Last updated: November 8, 2026

The Medicines Company sued Hospira in the U.S. District Court for the District of Delaware after Hospira filed an abbreviated new drug application seeking approval for a generic version of Angiomax, the bivalirudin injection product. The dispute concerned patents covering bivalirudin purity, pharmaceutical batches, and manufacturing processes.

The principal patents were U.S. Patent Nos. 7,582,727 and 7,598,343. The litigation produced multiple Federal Circuit decisions addressing the on-sale bar, patent validity, product-by-process claims, and infringement. The case is a leading pharmaceutical patent decision because the Federal Circuit held that manufacturing transactions involving a contract manufacturer did not constitute a commercial sale of the patented product for purposes of pre-AIA 35 U.S.C. § 102(b).

What was The Medicines Company v. Hospira, 1:10-cv-00700?

The Medicines Company filed the action in 2010 against Hospira after receiving notice of Hospira’s Paragraph IV certification concerning Angiomax patents. Angiomax contains bivalirudin, a direct thrombin inhibitor used as an anticoagulant during percutaneous coronary intervention and related cardiovascular procedures.

The case involved an ANDA-based patent infringement claim under the Hatch-Waxman Act. Hospira’s ANDA proposed a generic bivalirudin product. The Medicines Company alleged that Hospira’s proposed product would infringe patents covering the composition and manufacture of pharmaceutical-grade bivalirudin.

Item	Details
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:10-cv-00700
Plaintiff	The Medicines Company
Defendant	Hospira Inc.
Brand product	Angiomax
Active ingredient	Bivalirudin
Regulatory pathway	ANDA
Core patents	U.S. Patent Nos. 7,582,727 and 7,598,343
Main issues	On-sale bar, obviousness, infringement, product-by-process claims, manufacturing transactions
Key appellate citations	805 F.3d 1357; 827 F.3d 1363

Which patents protected Angiomax in the Hospira litigation?

The principal patents concerned bivalirudin batches with controlled impurity levels and manufacturing methods designed to produce a commercially usable drug product.

U.S. Patent No. 7,582,727

The '727 patent covered pharmaceutical compositions and batches of bivalirudin with specified purity characteristics. The patent addressed impurities generated during synthesis and the need to produce bivalirudin at a purity level suitable for injection.

The claims were important because they were directed to the drug product and its impurity profile rather than only to the underlying chemical structure of bivalirudin.

U.S. Patent No. 7,598,343

The '343 patent covered processes for preparing bivalirudin pharmaceutical batches. The claimed process addressed manufacturing controls used to reduce impurities and improve batch quality.

The patent raised a recurring Hatch-Waxman issue: whether an ANDA product made by a process outside the United States could infringe a U.S. process patent under 35 U.S.C. § 271(e)(2), and whether the resulting product could infringe product-by-process claims.

Earlier Angiomax patent

U.S. Patent No. 5,196,404 was an earlier Angiomax patent. Its term had substantially expired by the time of the Hospira litigation. The later patents, particularly the '727 and '343 patents, were the principal barriers to generic entry in the case.

What were the key litigation dates?

Date	Event
2010	The Medicines Company filed the Delaware infringement action against Hospira after Hospira’s Paragraph IV certification.
2014	The District of Delaware issued rulings addressing validity and the asserted bivalirudin patents.
2015	The Federal Circuit issued a decision addressing the validity of the asserted patents and the on-sale-bar dispute.
2016	The Federal Circuit held that the manufacturing transactions at issue were not commercial sales of the patented product under the applicable pre-AIA on-sale-bar standard.
2016 onward	The parties continued litigating validity and infringement issues on remand, including the effect of the Federal Circuit’s on-sale ruling.

The litigation generated more than one appellate decision. Citations to the case therefore require attention to the specific issue being analyzed.

What did the Federal Circuit hold about the on-sale bar?

The Federal Circuit held that the transactions between The Medicines Company and its contract manufacturer did not trigger the pre-AIA on-sale bar.

The relevant manufacturing activity occurred more than one year before the patent applications were filed. The district court treated the transactions as commercial sales that placed the invention on sale. The Federal Circuit reversed that analysis.

The court focused on the substance of the transactions. The Medicines Company retained title to the bivalirudin, controlled the manufacturing process, and used the contract manufacturer to produce commercial batches. The transactions were manufacturing services rather than sales of bivalirudin to a third-party purchaser.

The decision established several practical principles:

1. A contract manufacturer’s production of a patented product does not necessarily constitute a commercial sale of the product.
2. Retention of title by the patent owner is relevant to the on-sale-bar analysis.
3. A manufacturing-services agreement may be treated differently from a sale of the patented product.
4. The commercial exploitation of a manufacturing process does not automatically create a sale of the product made by that process.

The Federal Circuit’s decision was issued under the pre-America Invents Act version of Section 102(b). The AIA changed the statutory language, but the decision remains important for pre-AIA patents and for analysis of contract-manufacturing arrangements.

How did the court address patent validity?

The case raised both on-sale-bar and obviousness issues.

The district court initially found the asserted patents vulnerable to an on-sale-bar defense based on earlier manufacturing activity. The Federal Circuit rejected that ground. The appellate court did not hold that every validity issue had been resolved in The Medicines Company’s favor. It held that the specific commercial-sale theory used by the district court did not invalidate the patents.

The validity analysis also involved whether the claimed purity levels and manufacturing techniques would have been obvious to a person of ordinary skill in the art. The dispute included:

• The known difficulty of producing highly pure bivalirudin;
• The relationship between process conditions and impurity formation;
• The predictability of achieving the claimed purity profile;
• Whether the prior art supplied a reason to modify the manufacturing process;
• Whether the claimed product characteristics were inherent or unexpected.

The case illustrates that a patent owner can defeat an on-sale-bar defense while still facing separate obviousness and claim-construction challenges. A favorable ruling on one invalidity theory does not eliminate other routes to a generic launch.

Did Hospira’s ANDA product infringe the asserted patents?

The litigation involved infringement allegations tied to Hospira’s proposed generic product and manufacturing process. The Medicines Company argued that Hospira’s ANDA product would meet the limitations of the bivalirudin composition claims and that the ANDA filing itself created an artificial act of infringement under Section 271(e)(2).

The infringement analysis required the court to examine:

• The impurity levels in Hospira’s proposed bivalirudin product;
• Whether the claims were product claims or product-by-process claims;
• Whether process limitations should be imported into the infringement analysis;
• The manufacturing steps identified in Hospira’s ANDA;
• Whether the proposed product was reasonably certain to infringe after FDA approval.

For product-by-process claims, the Federal Circuit has generally treated the product characteristics as central to infringement. A process limitation may have a stronger role in validity than in infringement, depending on the claim language and controlling precedent. That distinction made claim construction and proof of the finished product particularly important.

What was the Paragraph IV challenge?

Hospira’s ANDA included a Paragraph IV certification asserting that the relevant Angiomax patents were invalid, unenforceable, or not infringed.

A Paragraph IV certification triggers potential patent litigation under the Hatch-Waxman Act. The filing of the infringement action generally creates a 30-month stay of FDA approval, subject to statutory exceptions and subsequent court orders.

The commercial consequences were substantial because the dispute involved a parenteral anticoagulant with an established hospital market. Hospira’s ability to launch depended on the outcome of the patent case, the expiration or invalidation of the listed patents, and any settlement or license arrangement between the parties.

What was the FDA and Orange Book status?

Angiomax was approved by the FDA as a bivalirudin injection product. The litigation involved small-molecule drug regulation under the ANDA pathway, not the biologics license application and biosimilar pathways.

Regulatory issue	Analysis
FDA pathway	ANDA
Reference product	Angiomax
Active ingredient	Bivalirudin
Patent certification	Paragraph IV
Regulatory listing	Orange Book-listed patents were central to the dispute
Exclusivity type	Small-molecule Hatch-Waxman exclusivity
Biosimilar relevance	None; bivalirudin is a chemically synthesized small molecule
Main regulatory barrier	Patent certification and litigation stay

The case did not involve biosimilar interchangeability, reference-product exclusivity under the Biologics Price Competition and Innovation Act, or a biologic manufacturing comparability dispute.

When did the Angiomax patents expire?

The principal later Angiomax patents had terms extending into the late 2020s, subject to statutory adjustments, disclaimers, and any applicable patent-term calculations.

Patent	General subject matter	Reported expiration framework
U.S. 5,196,404	Earlier bivalirudin/Angiomax protection	Expired before or around the beginning of the Hospira litigation
U.S. 7,582,727	Bivalirudin pharmaceutical composition and purity characteristics	Term extending into 2028
U.S. 7,598,343	Bivalirudin manufacturing process	Term extending into 2028

Patent expiration must be separated from FDA exclusivity. Patent expiration does not itself establish the date of ANDA approval, and FDA approval may be affected by a Paragraph IV stay, pediatric exclusivity, settlement restrictions, or other regulatory events.

Did the parties reach a settlement agreement?

The reported appellate decisions establish the principal legal holdings, but the public case history is more significant for its judicial rulings than for a broadly documented commercial settlement structure.

A settlement analysis should distinguish among:

• A judgment following trial;
• A consent judgment;
• A license permitting an earlier generic launch;
• A covenant not to sue;
• A dismissal after resolution of the ANDA dispute.

The Federal Circuit’s reported decisions should not be treated as evidence of a settlement unless the docket or a settlement filing expressly establishes one.

What litigation risks did the case create for generic launch?

Hospira faced several launch risks:

Patent validity risk

The generic applicant had to overcome the asserted patents on invalidity or noninfringement grounds. The on-sale-bar defense failed at the Federal Circuit, leaving other validity theories to be evaluated separately.

Claim-construction risk

The meaning of purity limitations, impurity thresholds, and process language could determine whether Hospira’s proposed product fell within the claims.

Manufacturing-disclosure risk

Because the case involved process patents, the manufacturing information in the ANDA was central. Changes to the manufacturing process could affect both infringement exposure and FDA review.

Injunction risk

A finding of infringement could delay launch through an injunction or final judgment tied to patent expiration. A finding of invalidity or noninfringement could permit launch before the listed patent terms ended.

Contract-manufacturing risk

The case changed how pharmaceutical companies evaluate contract manufacturing arrangements. Service agreements, title retention, batch ownership, and payment structure can influence whether manufacturing activity creates an on-sale-bar problem.

How strong was The Medicines Company’s patent estate?

The estate had meaningful technical value because it protected more than the bivalirudin molecule itself. It covered quality attributes and manufacturing methods that could be difficult to design around while maintaining commercial-scale injectable-product quality.

Its strengths included:

• Protection directed to pharmaceutical-grade bivalirudin;
• Claims tied to impurity control;
• Process protection covering manufacturing methods;
• Orange Book leverage in an ANDA dispute;
• A significant remaining term for the later patents at the time of filing.

Its vulnerabilities included:

• Dependence on complex claim construction;
• Obviousness challenges based on known peptide and anticoagulant manufacturing methods;
• Product-by-process claim issues;
• Difficulty proving infringement based on confidential manufacturing operations;
• The possibility of noninfringing process redesign.

The Federal Circuit’s on-sale-bar ruling strengthened the estate against that specific invalidity defense but did not eliminate the commercial and technical risks associated with process-patent enforcement.

What was the competitive and commercial impact?

The case concerned competition between The Medicines Company’s Angiomax franchise and Hospira’s generic bivalirudin product. The principal commercial issue was whether Hospira could enter the hospital anticoagulant market before expiration of the later patents.

The likely competitive effects were:

• Reduced pricing for bivalirudin after generic entry;
• Pressure on Angiomax revenue and hospital formulary share;
• Greater leverage for Hospira in settlement discussions;
• Increased importance of manufacturing-process patents for injectable products;
• Potential erosion of brand sales even before full patent expiry if an authorized generic or licensed competitor entered.

The record does not support a reliable revenue-loss figure without verified company sales data, launch timing, and market-share information.

What does this case mean for pharmaceutical patent strategy?

The litigation has four strategic implications.

First, contract manufacturing should be structured with the on-sale bar in mind. Ownership of materials, title to batches, payment terms, and the purpose of the transaction can affect patent validity.

Second, formulation and purity patents can provide practical protection after a basic compound patent expires. These patents are strongest when the claimed quality attributes are difficult to achieve predictably and are supported by comparative data.

Third, manufacturing patents require close alignment between patent claims and the information disclosed in the ANDA. Broad process language may create enforcement value, but it can also increase validity risk.

Fourth, Paragraph IV litigation should be analyzed as a portfolio dispute. A generic challenger may succeed against one patent while remaining blocked by another composition, formulation, method-of-use, or process patent.

Key Takeaways

• The Medicines Company sued Hospira in Delaware over a Paragraph IV ANDA for generic bivalirudin.
• The dispute centered on U.S. Patent Nos. 7,582,727 and 7,598,343.
• The Federal Circuit held that contract-manufacturing transactions were not commercial sales of the patented product under the pre-AIA on-sale bar.
• The case involved purity, impurity control, product-by-process claims, and manufacturing methods.
• Bivalirudin is a small-molecule drug, so biosimilar law was not relevant.
• The later Angiomax patents had terms extending into 2028 under the applicable patent-term framework.
• The decision remains important for pharmaceutical contract manufacturing and pre-AIA on-sale-bar analysis.

FAQs About The Medicines Company v. Hospira

Was The Medicines Company v. Hospira a biologic or biosimilar case?

No. The case involved bivalirudin, a chemically synthesized small-molecule drug regulated through the ANDA pathway. It was not a biosimilar case.

What drug was at issue in the Hospira patent litigation?

The drug was Angiomax, whose active ingredient is bivalirudin. The product is an injectable direct thrombin inhibitor used as an anticoagulant.

What is the importance of the 827 F.3d 1363 decision?

The Federal Circuit held that manufacturing transactions involving The Medicines Company and its contract manufacturer did not constitute commercial sales of the patented bivalirudin product for purposes of the pre-AIA on-sale bar.

Did the case concern formulation patents?

Yes. The asserted patent estate included claims directed to pharmaceutical-grade bivalirudin, impurity levels, purity characteristics, and manufacturing processes used to produce the injectable product.

Could a generic company design around the Angiomax patents?

Potentially. A design-around could involve a different manufacturing process or a product that does not meet the claimed impurity or purity limitations. The feasibility would depend on the precise claim language, ANDA process, and laboratory evidence.

References

1. The Medicines Co. v. Hospira, Inc., 805 F.3d 1357 (Fed. Cir. 2015).

2. The Medicines Co. v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016).

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. U.S. Department of Commerce.

5. U.S. District Court for the District of Delaware. (2010). The Medicines Company v. Hospira, Inc., No. 1:10-cv-00700. PACER docket records.